164 related articles for article (PubMed ID: 23131388)
1. Early development of the metabolic syndrome after chemotherapy for testicular cancer.
de Haas EC; Altena R; Boezen HM; Zwart N; Smit AJ; Bakker SJ; van Roon AM; Postma A; Wolffenbuttel BH; Hoekstra HJ; van Leeuwen FE; Sleijfer DT; Gietema JA
Ann Oncol; 2013 Mar; 24(3):749-55. PubMed ID: 23131388
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
4. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy.
Lubberts S; Boer H; Altena R; Meijer C; van Roon AM; Zwart N; Oosting SF; Kamphuisen PW; Nuver J; Smit AJ; Mulder AB; Lefrandt JD; Gietema JA
Eur J Cancer; 2016 Aug; 63():180-8. PubMed ID: 27322917
[TBL] [Abstract][Full Text] [Related]
5. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
6. Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study.
Blaes AH; Mulrooney DA; Vogel RI; Solovey A; Hebbel R; Peterson BA; Neglia JP; Biewen C; Konety SH; Duprez DA
Vasc Health Risk Manag; 2018; 14():205-211. PubMed ID: 30237722
[TBL] [Abstract][Full Text] [Related]
7. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
[TBL] [Abstract][Full Text] [Related]
8. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
9. Re: Early development of the metabolic syndrome after chemotherapy for testicular cancer.
Richie JP
J Urol; 2014 Apr; 191(4):987. PubMed ID: 24703124
[No Abstract] [Full Text] [Related]
10. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.
Nuver J; Smit AJ; van der Meer J; van den Berg MP; van der Graaf WT; Meinardi MT; Sleijfer DT; Hoekstra HJ; van Gessel AI; van Roon AM; Gietema JA
J Clin Oncol; 2005 Dec; 23(36):9130-7. PubMed ID: 16301596
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Willemse PM; Burggraaf J; Hamdy NA; Weijl NI; Vossen CY; van Wulften L; van Steijn-van Tol AQ; Rosendaal FR; Osanto S
Br J Cancer; 2013 Jul; 109(1):60-7. PubMed ID: 23660945
[TBL] [Abstract][Full Text] [Related]
12. Components of the metabolic syndrome in long-term survivors of testicular cancer.
Haugnes HS; Aass N; Fosså SD; Dahl O; Klepp O; Wist EA; Svartberg J; Wilsgaard T; Bremnes RM
Ann Oncol; 2007 Feb; 18(2):241-8. PubMed ID: 17060482
[TBL] [Abstract][Full Text] [Related]
13. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors.
Haugnes HS; Aass N; Fosså SD; Dahl O; Klepp O; Wist EA; Wilsgaard T; Bremnes RM
J Cancer Surviv; 2008 Sep; 2(3):128-37. PubMed ID: 18792787
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.
Lubberts S; Groot HJ; de Wit R; Mulder S; Witjes JA; Kerst JM; Groenewegen G; Lefrandt JD; van Leeuwen FE; Nuver J; Schaapveld M; Gietema JA
J Clin Oncol; 2023 Jul; 41(19):3512-3522. PubMed ID: 37071834
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
[TBL] [Abstract][Full Text] [Related]
16. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment.
Skoogh J; Steineck G; Stierner U; Cavallin-Ståhl E; Wilderäng U; Wallin A; Gatz M; Johansson B;
Acta Oncol; 2012 Feb; 51(2):185-97. PubMed ID: 21851186
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.
Bucher-Johannessen C; Page CM; Haugen TB; Wojewodzic MW; Fosså SD; Grotmol T; Haugnes HS; Rounge TB
Clin Epigenetics; 2019 Dec; 11(1):179. PubMed ID: 31796056
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; Nuver J; de Wit R; Gietema JA; ten Bokkel Huinink WW; Rodrigus PT; Schimmel EC; Aleman BM; van Leeuwen FE
J Clin Oncol; 2006 Jan; 24(3):467-75. PubMed ID: 16421423
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Changes in Children that Received Chemotherapy.
Soto-Vega E; Carrillo-Vicente LS; Vázquez JC; Pérez de Celis Herrero MC; Muñoz-Pérez MJ
J Pediatr Hematol Oncol; 2019 Aug; 41(6):448-451. PubMed ID: 30676437
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer.
Gietema JA; Sleijfer DT; Willemse PH; Schraffordt Koops H; van Ittersum E; Verschuren WM; Kromhout D; Sluiter WJ; Mulder NH; de Vries EG
Ann Intern Med; 1992 May; 116(9):709-15. PubMed ID: 1558341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
